Cynthia So-Osman

TL;DR: The relative paucity of strong evidence to answer many of the PICO questions supports the need for additional research and an international consensus for accepted definitions and hemoglobin thresholds, as well as clinically meaningful end points for multicenter trials.

TL;DR: To continually assess, as more evidence becomes available, whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in treatment of people with COVID-19, a first living update of this review is published.

TL;DR: This work systematically searched for relevant studies addressing the transfusion chain—from donor, through collection and processing, to patients—to provide a synthesis of the published literature and guidance during times of potential or actual shortage.

TL;DR: Assessing whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19 found all-cause mortality at hospital discharge, improvement of clinical symptoms, grade 3 and 4 adverse events, and serious adverse events were reported.

TL;DR: This is a protocol for a Cochrane Review to assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention.